Sign in

You're signed outSign in or to get full access.

Brandon Foakes

Research Analyst at H.C. Wainwright & Co.

Brandon Foakes is an Equity Research Analyst at H.C. Wainwright & Co., specializing in biotechnology sector coverage with a particular focus on companies such as CorMedix. He actively participates in earnings calls and provides detailed analysis that supports institutional investor decision-making, contributing to successful forecasts and recommendations tracked by research platforms. Foakes began his analyst career at H.C. Wainwright and has become a notable voice in biotech research, leveraging in-depth industry knowledge to deliver actionable insights. His credentials include FINRA registration and securities licensure, validating his professional status as a registered securities analyst.

Brandon Foakes's questions to CorMedix (CRMD) leadership

Question · Q3 2025

Brandon Foakes asked about the progression of DefenCath's inpatient opportunity, particularly for 2026, considering Melinta's scale. He also inquired about the NIAID (Telfera) investment, its commercial fit, potential for strong EBITDA accretion, and any required investment if the option is exercised.

Answer

CEO Joe Todisco reported good, steady growth in DefenCath inpatient sales this year, expecting further lift in 2026 as the new combined field team begins promotion in January. He noted better pricing and higher revenue per patient in the inpatient setting. Regarding NIAID, Todisco expressed enthusiasm for the product's fit with the commercial infrastructure and confirmed that while some marketing investment would be required if acquired, it aligns well with existing call points.

Ask follow-up questions

Fintool

Fintool can predict CorMedix logo CRMD's earnings beat/miss a week before the call

Question · Q3 2025

Brandon Foakes from H.C. Wainwright & Co. asked about the progress and 2026 expectations for the DefenCath inpatient opportunity, particularly considering the scale and relationships brought by the Melinta integration. He also questioned the company's view on the Talphera investment, its fit with the commercial infrastructure, potential for EBITDA accretion, and any required material investment.

Answer

CEO Joe Todisco noted good, steady growth for DefenCath in the inpatient setting, though smaller than outpatient. He anticipates further lift in 2026 as the new combined field team, trained in December, begins inpatient promotion in January, highlighting better pricing and higher revenue per patient in this segment. Regarding Talphera, Todisco stated the strategic investment was due to product fit with commercial infrastructure, but acknowledged that some marketing investment would likely be required if acquired, though sales deployment aligns well with existing call points.

Ask follow-up questions

Fintool

Fintool can write a report on CorMedix logo CRMD's next earnings in your company's style and formatting